Targeting protein prenylation for cancer therapy - Wikidata - awgldk - TriplyDB

Targeting protein prenylation for cancer therapy

Targeting protein prenylation for cancer therapy

http://www.wikidata.org/entity/Q33679239

about

Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling Regulation of TOR by small GTPases Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment Approaches of targeting Rho GTPases in cancer drug discovery Protein prenylation and synaptic plasticity: implications for Alzheimer's disease Small G proteins in the cardiovascular system: physiological and pathological aspects P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance.Intracellular oxygen determined by respiration regulates localization of Ras and prenylated proteins.RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer Metalloprotein–Inhibitor Binding: Human Carbonic Anhydrase II as a Model for Probing Metal–Ligand Interactions in a Metalloprotein Active Site Pancreatic cancer, treatment options, and GI-4000 Translating discovery in zebrafish pancreatic development to human pancreatic cancer: biomarkers, targets, pathogenesis, and therapeutics Prenylome profiling reveals S-farnesylation is crucial for membrane targeting and antiviral activity of ZAP long-isoform Cellular FRET-Biosensors to Detect Membrane Targeting Inhibitors of N-Myristoylated Proteins Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis Global proteomic analysis of prenylated proteins in Plasmodium falciparum using an alkyne-modified isoprenoid analogue Targeting protein lipidation in disease Expansion of protein farnesyltransferase specificity using "tunable" active site interactions: development of bioengineered prenylation pathways.A novel role of farnesylation in targeting a mitotic checkpoint protein, human Spindly, to kinetochores Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation.Niche-based screening identifies small-molecule inhibitors of leukemia stem cells Tipifarnib prevents development of hypoxia-induced pulmonary hypertension.Comprehensive pharmacological profiling of neurofibromatosis cell lines.In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida Manumycin induces apoptosis in prostate cancer cells The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway A combination of metabolic labeling and 2D-DIGE analysis in response to a farnesyltransferase inhibitor facilitates the discovery of new prenylated proteins.Protein Lipidation As a Regulator of Apoptotic Calcium Release: Relevance to Cancer.Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms.Engineering protein farnesyltransferase for enzymatic protein labeling applications.An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo.Oncogenic KRAS signalling in pancreatic cancer.Solid-phase synthesis of C-terminal peptide libraries for studying the specificity of enzymatic protein prenylation.Development of synthetic lethality anticancer therapeutics.Differential effects of lovastatin on cisplatin responses in normal human mesothelial cells versus cancer cells: implication for therapy.Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1.Protein prenylation: enzymes, therapeutics, and biotechnology applications.Global profiling of protein lipidation using chemical proteomic technologies

P2860

Q24293500-D7AEC570-F9E3-4895-B578-11EC73130606 Q24598385-3E98117F-CF0A-4BB7-9CBA-E475CF2DB9ED Q26740619-43BC3730-37D3-45E6-A08E-AB7AB897672E Q26751520-D9523887-8F3A-4A37-81B3-B4A6509738ED Q26851300-F30990EB-E95F-4764-B5BC-2ACD6CEAFE1C Q26858942-1A221905-1C9F-48A9-898D-C002A2573D64 Q27010607-0FCF2572-48AB-42BB-B5A1-E87D2E05DE63 Q27308938-01D59924-01A7-4664-A04A-8C9E5FC1A351 Q27329552-3D11D143-B2E1-4251-9C48-7460DD1188BB Q27670969-F5843906-6C59-4E0C-A134-8FDA1926C570 Q27678293-FE151FCE-E1B2-41BB-A050-81634AEF40C3 Q28083814-C2359300-C603-42D3-90AA-6FDED3246D8A Q28468696-722586D8-BE08-42A8-B2C7-8F376C3BAE90 Q28507655-9FAD9A84-BA1C-42DE-894F-B96F57BED43C Q28534102-D34446C6-AC45-4AD3-8C36-9A1D4295AEA4 Q28539314-3D00F3E6-5009-4F00-B02C-3BA9971072FC Q28817814-E5508EB7-1DC0-4499-B0E4-DDA70909515F Q30413212-408FFAFE-3620-4A64-8804-15C120FE17D4 Q30421452-2041AC73-3F24-4EC6-BF4E-DE5FD5A8B3C5 Q30635394-F4D92F3C-A88C-4A8C-AE94-DA8098B87C1F Q30846580-6513A7E2-3D2A-4FD6-BEF6-25A304DF1B95 Q33563509-8AE6217E-BE61-43E3-901F-3D49E8615966 Q33614140-F879D63D-E023-4FF3-8BDE-6C15616505F0 Q33622690-27E1D568-9A30-414F-9DC8-8BF0827B7B9F Q33644292-76B81DB9-2231-4A40-9FE7-3B5AD63B2332 Q33689772-7795FF83-B9ED-477D-8970-962796733C74 Q33757009-925CC69D-51BE-4530-A8C9-84A4A917F1C0 Q33760617-378A09C5-932D-4BEE-91A4-D8F5FDFA35B9 Q33849385-F151FA69-D77F-4EB0-B976-6FEE4F84AA7A Q33886255-599C3101-F33E-4148-8988-D6942A259674 Q33921079-434B01B2-FC2F-4243-9A92-A3474A82DF20 Q34028492-DF3C5A76-8D0E-465C-8D76-5918D68B7799 Q34113460-0C3EE8C2-0A00-4D77-885B-FC7DF241FB56 Q34333107-2162A15C-F275-42CC-8E0C-BA23CC163F12 Q34380368-0CA92E34-04E2-4C86-B905-DA136F63FD24 Q34428844-8A37EE17-4EF7-41D4-8EC5-9FAFE51A7AFF Q34537580-1191CCE8-774C-4508-BCCC-A9602D9487B1 Q34582195-07BFFFCA-4C84-41D3-8FA8-C25589033FB3 Q34992469-EE6CFCE5-7AF3-4DD4-9CB9-1C1BA29942D8 Q35057612-70B0ED27-D013-4C71-BC05-6429D5DCCE4E

P2860

Targeting protein prenylation for cancer therapy

http://www.wikidata.org/entity/Q33679239

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Targeting protein prenylation for cancer therapy

@ast

Targeting protein prenylation for cancer therapy

@en

type

label

Targeting protein prenylation for cancer therapy

@ast

Targeting protein prenylation for cancer therapy

@en

prefLabel

Targeting protein prenylation for cancer therapy

@ast

Targeting protein prenylation for cancer therapy

@en

P1433

Q33679239-D977833D-D675-4439-A058-37BF78CC96FC

P1476

Q33679239-513B3E29-32AF-410F-AE20-7C5F2466E9C9

P2093

Q33679239-76FBB802-DEBE-47F9-AD0C-8DA16FD968F3

Q33679239-9778E732-7D16-4979-991A-463667212195

Q33679239-B1AB9F76-92F6-4DEF-80C3-849F97186117

P2860

Q33679239-0269D5D8-250F-45A6-83E9-5210A65329E7

Q33679239-05C0EF81-C253-44D8-8C8F-5E9246C7F737

Q33679239-06AFB752-A238-449E-9391-617E102B4B12

Q33679239-07DE1EF7-A17F-4CBA-8697-B2CD39CD0B46

Q33679239-09044AF3-E66A-41CC-B743-629CAA27D107

Q33679239-0AB860FF-68B2-49F8-AF63-EFBE1B7E688C

Q33679239-0B564713-0A4A-4625-B07F-F00022DAF070

Q33679239-0BF6B4A7-EE20-46F0-B262-FE633F21CBA8

Q33679239-0D01B4F3-5E66-4254-8E8F-3570FE55A379

Q33679239-0D769DAC-D5D1-4219-861E-B02E0E6CDE1B

P2888

Q33679239-BE7CD402-282E-41A0-9519-CB4B879EA89D

P304

Q33679239-656B06A8-ACC2-4CD8-8E43-23E54AE38E34

P31

Q33679239-D0DC0D85-1D83-4302-8D06-085B4C8AE283

P356

Q33679239-9AF7C84F-58F9-4D71-B668-0074D058ADE4

P407

Q33679239-185B6793-1972-4FC1-9566-9FB989C980E0

P433

Q33679239-157A9945-03C6-4654-8163-C450F262D8F5

P478

Q33679239-7881A595-5E46-40F3-81CD-B959521FBB68

P577

Q33679239-37645F28-63D7-4D7C-95B3-8BC6CF7F4145

P6179

Q33679239-52638184-2695-42FD-8F55-7FFDACE0A898

P698

Q33679239-BF0F6728-2185-45B1-B49F-2A7F22210F7E

P932

Q33679239-94A43897-7F9F-458D-A8F1-FBEA9C34DE54

P356

P1433

Nature Reviews Cancer

P1476

Targeting protein prenylation for cancer therapy

@en

P2093

Andrew D Hamilton

http://www.w3.org/2001/XMLSchema#string

Norbert Berndt

http://www.w3.org/2001/XMLSchema#string

Saïd M Sebti

http://www.w3.org/2001/XMLSchema#string

P2860

Rab6 is phosphorylated in thrombin-activated platelets by a protein kinase C-dependent mechanism: effects on GTP/GDP binding and cellular distribution

RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer

Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth

Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit

Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis

Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity

The tumor suppressor PP2A Abeta regulates the RalA GTPase

Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K

KSR, a novel protein kinase required for RAS signal transduction

The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner

P2888

P304

775-791

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRC3151

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1027538896

http://www.w3.org/2001/XMLSchema#string

P698

22020205

http://www.w3.org/2001/XMLSchema#string

P932

4037130

http://www.w3.org/2001/XMLSchema#string